Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for ...

Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies ...

A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...

Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition ...

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Fallopian Tube Cancer.

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...